Obsessive-compulsive spectrum disorders

Dialogues in Clinical Neuroscience

Volumn 5, Issue 3, 2003, Pages 259-271

  Allen, Andrea ^a   King, Audrey ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Asperger's disorder; Autism; Body dysmorphic disorder; Impulsivity; Obsessive compulsive disorder; Pathological gambling; Sexual compulsivity

Indexed keywords

BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PAROXETINE; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

ARTICLE; AUTISM; BEHAVIOR THERAPY; BODY DYSMORPHIC DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMPULSION; HAIR LOSS; HUMAN; LIBIDO DISORDER; NEUROPATHOLOGY; OBSESSION; OBSESSIVE COMPULSIVE DISORDER; PATHOLOGICAL GAMBLING; PREVALENCE; SEXUAL BEHAVIOR; SEXUAL DEVIATION; SIDE EFFECT; SKIN MANIFESTATION;

EID: 0344010603     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (152)

1. Hollander E. Obsessive-Compulsive-Related Disorder. Washington, DC: American Psychiatric Press; 1993.
2. Hollander E, Wong CM. Obsessive-compulsive spectrum disorders. J Clin Psychiatry. 1995;56(suppl 4):7-12.
3. Hollander E, Rosen J. Obsessive-compulsive spectrum: a review. In: Maj M, Santorius N, Okasha A, Zohar J, eds. Obsessive-Compulsive Disorder. New York, NY: John Wiley & Sons; 2000.
4. Phillips KA. The obsessive-compulsive spectrums. Psychiatr Clin N Am. 2002;25:791-809.
5. Baxter LR, Schwartz JM, Guze BH, Bergman K, Szuba MP. Neuroimaging in obsessive-compulsive disorder: seeking the mediating neuroanatomy. In: Jenike MA, Baer L, Minichiello W, eds. Obsessive-Compulsive Disorders: Practical Management. 2nd ed. Chicago, III: Year Book Medical Publishers; 1990:167-188.
6. Rauch SL, Baxter LR. Neuroimaging of OCD and related disorders. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Practical Management. Boston, Mass: Mosby; 1998:289-317.
7. Hollander E. Obsessive-compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors. Int Clin Psychopharmacol. 1996;11(suppl 5):75-87.
8. Myers JK, Weissman MM, Tischler GL, et al. Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry. 1984;41:959-967.
9. Rasmussen SA, Tsuang MT. DSM-III obsessive-compulsive disorder: clinical characteristics and family history. Am J Psychiatry. 1986;143:317-322.
10. Weissman MM, Bland RC, Canino GJ, et al. The cross-national epidemiology of obsessive-compulsive disorder. J Clin Psychiatry. 1994;55(suppl 3):5-10.
11. Foa EB, Kozak MJ, Goodman WK, Hollander E, Jenike MA, Rasmussen SA. DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry. 1995;152:90-96.
12. Horwath E, Weissnam MM. The epidemiology and cross-national presentation of obsessive-compulsive disorder. Psychiatr Clin N Am. 2000;23:493-507.
13. Goodwin DW, Guze SB, Robbins E. Follow-up studies in obsessive neurosis. Arch Gen Psychiatry. 1969;20:182-187.
14. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1990;47:577-585.
15. Leonard H, Swedo SE, Rapoport J, et al. Treatment of childhood obsessive-compulsive disorder with clomipramine and desipramine: a double-blind crossover comparison. Arch Gen Psychiatry. 1989;46:1088-1092.
16. Stein DJ. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry. 2000;47:296-304.
17. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder. J Clin Psychiatry. 1990;51(suppl):36-43.
18. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23: 563-586.
19. Baxter LR, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49:681-689.
20. Saxena S, Brody AL, Ho ML, et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry. 2002;59:250-261.
21. Hollander E, Kaplan A, Allen A, Cartwright C. Pharmacotherapy for obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23:643-656.
22. Montgomery SA, Kasper S, Stein DJ, Bang Hedgaard K, Lemming OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001;16:75-86.
23. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48:730-738.
24. Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1993;3:143-152.
25. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:559-567.
26. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989;46:36-44.
27. Jenike MA, Hyman S, Baer L, Holland A, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry. 1990;147:1209-1215.
28. Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham D. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry. 2003. In press.
29. Chouinard G, Goodman W, Greist JH, et al. Results of a double-blind placebo-controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990;26:279-284.
30. Greist J, Chouinard G, Duboff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289-295.
31. Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2003;64:546-550.
32. Rasmussen SA, Baer L, Eisen J, Shera D. Previous SRI treatment and efficacy of sertraline for OCD: combined analysis of 4 multicenter trials. Poster presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego, Calif, May 17-22, 1997.
33. Ackerman DL, Greenland S, Bystritsky A. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1998;18:185-192.
34. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry. 1992;53(suppl 4):29-37.
35. Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacologic management of obsessive compulsive disorder. J Clin Psychiatry. 1993;54 (suppl 6):4-9.
36. Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive-compulsive disorder: current strategies. J Clin Psychiatry. 1994; 55(suppl 3):11-17.
37. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry. 1995;166:424-443.
38. Hollander E, Pallanti S. Current and experimental therapeutics of obsessive-compulsive disorder. In: Davis K, Charney D, Coyle J, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:1647-1664.
39. Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48:922-927.
40. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry. 2002;159:88-95.
41. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1988;145:1521-1525.
42. Jenike MA. Drug treatment of obsessive-compulsive disorders. In: Jenike MA, Baer L, Minichiello W, eds. Obsessive-Compulsive Disorders: Practical Management. New York, NY: Mosby; 1998.
43. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794-801.
44. Hollander E, Baldini Rossi N, Sood, E, Pallanti S. Risperidone augmentation in SRI-resistant OCD: a preliminary double-blind, placebo controlled study. Int J Neuropsychopharmacol. 2003. In press.
45. Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry. 1999;60:524-527.
46. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 2000;96:91-98.
47. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2000;61:514-517.
48. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry. 2001;46:356-358.
49. Crocq MA, Leclercq P, Guillon MS, Bailey PE. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. Eur Psychiatry. 2002;17:296-297.
50. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:302-308.
51. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1990;147:652-654.
52. Jenike MA. An update on obsessive-compulsive disorder. Bull Menninger Clin. 2001;65:4-25.
53. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry. 1999;14:101-106
54. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus U, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2000;10:165-169.
55. Expert Consensus Panel for Obsessive-Compulsive Disorder. Treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(suppl 4):3-28.
56. Meyer V. Modification of expectations in cases with obsessional rituals. Behav Res Ther. 1966;4:273-280.
57. Christensen H, Hadzi-Pavlovic D, Andrews G, Mattick R. Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1987;55:701-711.
58. Cox BJ, Swinson RP, Morrison BL, Paul S. Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. J Behav Ther Exp Psychiatry. 1993;24:149-153.
59. van Blakom AJLM, van Oppen P, Vermeulen AWA, et al. A meta-analysis on the treatment of obsessive-compulsive disorder: a comparison of antide-pressants, behavior, and cognitive therapy. Clin Psychol Rev. 1994;14:359-381.
60. Abramowitz JS. Does cognitive-behavioral therapy cure obsessive-compulsive disorder? A meta-analytic evaluation of clinical significance. Behav Ther. 1998;29:339-355.
61. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ. Behavioral versus pharmacological treatments of obsessive-compulsive disorder: a meta-analysis. Psychopharmacology. 1998;136:205-216.
62. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision. Washington, DC: American Psychiatric Association; 2000.
63. Simeon D, Hollander E, Stein DJ, Cohen L, Aronowitz B. Body dysmorphic disorder in the DSM-IV field trial for obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1207-1209.
64. Rich N, Rosen JC, Orosan PG, Reiter JT. Prevalence of body dysmorphic disorder in non-clinical populations. Paper presented at the meeting of the Association for Advancement of Behavior Therapy, Boston, Mass. November 1992.
65. Mayville S, Katz RC, Gipson MT, Cabral K. Assessing the prevalence of body dysmorphic disorder in an ethnically diverse group of adolescents. J Child Fam Stud. 1999;8:357-362.
66. Zimmerman M, Mattia JI, Phillips KA. Screening for body dysmorphic disorder in an outpatient clinic. Syllabus and Proceedings Summary, American Psychiatric Association 149th Annual Meeting. New York, NY: American Psychiatric Association; 1996.
67. Phillips KA, Diaz SF. Gender differences in body dysmorphic disorder. J Nerv Ment Dis. 1997;185:570-577.
68. Phillips KA, McElroy SL, Keck PE, Hudson J, Pope HG. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull. 1994;30:179-186.
69. Rauch SL, Phillips KA, Segal E, et al. A preliminary morphometric magnetic resonance imaging study of regional brain volumes in body dysmorphic disorder. Psychiatry Res. 2003;122:13-19.
70. Hollander E, Allen A, Kwan J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder. Arch Gen Psychiatry. 1999;S6:1033-1039.
71. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59:381-388.
72. Phillips KA, McElroy SL, Hudson JI, Pope HG Jr. Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? J Clin Psychiatry. 1995;56(suppl 4):41-51.
73. Hollander E. Treatment of obsessive-compulsive spectrum disorders with SSRIs. Br J Psychiatry. 1998;35(suppl):7-12.
74. Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chartreview study. J Clin Psychiatry. 2001;62:721-727.
75. Saxena S, Winograd A, Dunkin JJ, et al. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder. J Clin Psychiatry. 2001;62:67-72.
76. Munro A. Monosymptomatic hypochondriacal psychosis manifesting as delusions of parasitosis: a description of four cases successfully treated with pimozide. Arch Dermatol. 1978;14:940-943.
77. Zomer SF, DeWit RF, Van Bronswijk JE, Nabarro G, Van Vloten WA. Delusions of parasitosis. A psychiatric disorder to be treated by dermatologists? An analysis of 33 patients. Br J Dermatol. 1998;138:1030-1032.
78. Rosen JC, Reiter J, Orosan P. Cognitive-behavioral body image therapy for body dysmorphic disorder. J Consult Clin Psychol. 1995;63:263-269.
79. Wilhelm S, Otto MW, Lohr B, Deckersbach T. Cognitive behavior group therapy for body dysmorphic disorder: a case series. Behav Res Ther. 1999;37:71-75.
80. Veale D, Gournay K, Dryden W, et al. Body dysmorphic disorder: a cognitive behavioural model and pilot randomised controlled trial. Behav Res Ther. 1996;34:717-729.
81. McKay D, Todaro J, Neziroglu F, Campisi T, Moritz EK, Yaryura-Tobias JA. Body dysmorphic disorder: a preliminary evaluation of treatment and maintenance using exposure with response prevention. Behav Res Ther. 1997;3S:67-70.
82. Neziroglu F, Yaryura-Tobias JA. Exposure, response prevention, and cognitive therapy in the treatment of body dysmorphic disorder. J Behav Ther Exp Psychiatry. 1993;24:431-438.
83. Rosen JC, Cado S, Silberg NT, et al. Cognitive behavior therapy with and without size perception training for women with body image disturbance. Behav Ther. 1990;21:481-498.
84. National Gambling Impact and Behavior Study Commission. National Opinion Research Center, University of Chicago, Chicago, III. Available at: http://www.norc.uchicago.edu/new/gamb-fin.htm. Accessed 23 June 2003.
85. Shaffer HJ, Korn DA. Gambling and related mental disorders: a public health analysis. Annu Rev Public Health. 2002;23:171-212.
86. Volberg RA, Steadman HJ. Refining prevalence estimates of pathological gambling. Am J Psychiatry. 1988;145:502-505.
87. Welte JW, Barnes GM, Wieczorek WF, Tidwell MC, Parker J. Gambling participation in the US-results from a national survey. J Gambl Stud. 2002;18:313-337.
88. Lesieur HR, Rosenthal RJ. Pathological gambling: a review of the literature. J Gambl Stud. 1991;7:5-39.
89. Custer RL, Milt H. When Luck Runs Out. New York, NY: Facts on File Publications; 1985.
90. Grant JS, Kim SW. Gender differences in pathological gamblers seeking medication treatment. Compr Psychiatry. 2002;43:56-62.
91. Rosenthal RJ. Pathological gambling. Psychiatr Ann. 1992;22:72-78.
92. Rogers RD, Owen AM, Middleton HC, et al. Choosing between small, likely rewards and large, unlikely rewards activates inferior and orbital prefrontal cortex. J Neurosci. 1999;19:9029-9038.
93. Hollander E, DeCaria CM, Mari E, et al. Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry. 1998;155:1781-1783.
94. Hollander E, DeCaria CM, Finkell J, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry. 2000;47:813-817.
95. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:44-48.
96. Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli E. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:501-507.
97. Pallanti S, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry. 2002;63:1034-1039.
98. Moskowitz JA. Lithium and lady luck; use of lithium carbonate in compulsive gambling. N Y State J Med. 1980;80:785-788
99. Haller R, Hinterhuber H. Treatment of pathological gambling with carbamazepine. Pharmacopsychiatry. 1994;27:129.
100. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry. 2002;63:559-564.
101. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914-921.
102. Brown RIF. The effectiveness of Gamblers Anonymous. In: Eadington WR, ed. The Gambling Studies: Proceedings of the Sixth National Conference on Gambling and Risk Taking. Reno, Nev: Bureau of Business and Economic Research, University of Nevada; 1985.
103. Glen AM. The treatment of compulsive gamblers at the Cleveland VA Hospital, Brecksville Division. Paper presented at the 84th Annual convention of American Psychological Association, Washington, DC. September 1976.
104. Taber JI. Group psychotherapy with pathological gamblers. Paper presented at the 5th National Conference on Gambling and Risk Taking, South Lake Tahoe, Nev. 1981.
105. Russo AM, Taber JI, McCormick RA, Ramirez LF. An outcome study of an in-patient treatment program for pathological gambling. Hosp Commun Psychiatry. 1984;35:823-827.
106. Taber JI, McCormick RA, Russo AM, Adkins BJ, Ramirez LF. Follow-up of pathological gamblers after treatment. Am J Psychiatry. 1987;144:7S7-761.
107. Hodgins DC, Currie SR, el-Guebay N. Motivational enhancement and self-help treatments for problem gambling. J Consult Clin Psychol. 2001;69:50-57.
108. Victor R, Cruz C. Paradoxical intention in the treatment of compulsive gambling. Am J Psychother. 1967;21:808-814.
109. Barker J, Miller M. Aversion therapy for compulsive gamblers. J Nerv Ment Disord. 1968;146:285-302.
110. Goorney AB. Treatment of a compulsive horse race gambler by aversion therapy. Br J Psychiatry. 1968;114:329-333.
111. Seager CP. Treatment of compulsive gamblers using electrical aversion. Br J Psychiatry. 1970;117:545-553.
112. Koller KM. Treatment of poker-machine addicts by aversion therapy. Med J Aust. 1972;1:742-745.
113. McConaghy N, Blaszczynski A, Frankova A. Comparison of imaginal desensitisation with other behavioural treatments of pathological gambling. A 2- to 9-year follow-up. Br J Psychiatry. 1991;159:390-393.
114. Symes BA, Nicki RM. A preliminary consideration of cue-exposure, response-prevention treatment for pathological gambling behavior: two case studies. J Gambl Stud. 1997;13:145-157.
115. Sylvain C, Ladouceur R, Boisvert JM. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol. 1997;65:727-732.
116. Ladouceur R, Sylvain C, Letarte H, Giroux I, Jacques C. Cognitive treatment of pathological gamblers. Behav Res Ther. 1998;36:1111-1119.
117. Coleman E. Is your patient suffering from compulsive sexual behavior? Psychiat Ann. 1992;22:320-325.
118. Bremer JF. Serious juvenile sex offenders: treatment and long-term follow-up. Psychiatr Ann. 1992;22:326-332.
119. Goodman A. Sexual addiction. In: Lowinson JH, Ruiz R, Millman RG, Langrod JG, eds. Substance Abuse: A Comprehensive Textbook. Baltimore, Md: Williams & Wilkins; 1997.
120. Black DW, Kehrberg LL, Flumerfelt DL, Schlosser SS. Characteristics of 36 subjects reporting compulsive sexual behavior. Am J Psychiatry. 1997;154:243-249.
121. Gold SN, Heffner CL, Sexual addiction: many conceptions, minimal data. Clin Psychol Rev. 1998;18:367-381.
122. McElroy SL, Hudson JI, Pope H Jr, Keck PE Jr, Aizley HG. The DSM-III-R impulse control disorders not elsewhere classified: clinical characteristics and relationship to other psychiatric disorders. Am J Psychiatry. 1992;149: 318-327.
123. Carnes P. The obsessive shadow. Professional Counselor. 1998;13:15-17.
124. Stein DJ, Hollander E, Anthony D, et al. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. J Clin Psychiatry. 1992;53:267-271.
125. Kafka MP, Prentky R. Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry. 1992;53:351-358.
126. Kafka MR. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. Ann Clin Psychiatry. 1994;6:189-195.
127. Bradford J, Greenberg D, Gojer J, Martindale J, Goldberg M. Sertraline in the treatment of pedophilia: an open-label study. Presented at the 148th Annual Meeting of the American Psychiatric Association. Miami, Fla. 1995.
128. Greenberg D, Bradford J Curry S, O'Rourke A. A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study. Bull Am Acad Psychiatry Law. 1996;24:525-532.
129. Bartova D, Nahunek K, Svestka J. Pharmacological treatment of deviant sexual behaviour. Act Nerv Super (Praha). 1978;20:72-74.
130. Bartova D, Nahunek K, Svestka J, Hajnova R. Comparative study of prophylactic lithium and diethylstilbestrol in sexual deviants. Act Nerv Super (Praha) 1979;21:163-164.
131. Kafka MP. Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry. 1991;52:60-65.
132. Snaith RP, Collins SA. Five exhibitionists and a method of treatment. Br J Psychiatry. 1981;138:126-130.
133. Kruesi MJ, Fine S, Valladares L, Phillips RA Jr, Rapoport JL. Paraphilias: a double-blind crossover comparison of clomipramine versus desipramine. Arch Sex Behav. 1992;21:587-593.
134. Kafka MP, Hennen J. Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. J Clin Psychiatry. 2000;61:664-670.
135. Grossman LS, Martis B, Fichtner CG. Are sex offenders treatable? A research overview. Psychiatr Serv. 1999;50:349-361.
136. Shanahan M, Donato R. Counting the cost: estimating the economic benefit of pedophile treatment programs. Child Abuse Negl. 2001;25:541-555.
137. Maletzky BM, Steinhauser C. A 25-year follow-up of cognitive/behavioral therapy with 7275 sexual offenders. Behav Modif. 2002;26:123-147.
138. Hollander E, Wong C. Body dysmorphic disorder, pathological gambling and sexual compulsions. J Clin Psychiatry. 1995;56(suppl 4):7-12.
139. Fombonne E. The epidemiology of autism: a review. Psychol Med. 1999;29:769-786.
140. Gillot A, Furness F, Walter A. Anxiety in high-functioning children with autism. Autism. 2001;5:277-286.
141. Bejerot S, Nylander L, Lindstrom E. Autistic traits in obsessive-compulsive disorder. Nord J Psychiatry. 2001;55:169-176.
142. Bolton P, Pickles A, Murphy M, Rutter M. Autism, affective and other psychiatric disorders: patterns of familial aggregation. Psychol Med. 1998;28:385-395.
143. Piven J, Chase G, Landa R, et al. Psychiatric disorders in the parents of autistic individuals. J Acad Child Adolesc Psychiatry. 1991;35:471-478.
144. Buxbaum J, Silverman J, Smith C, et al. Evidence for susceptibility for autism on chromosome 2 and for genetic heterogeneity. Am J Hum Genet. 2001;68:1514-1520.
145. Wassink T, Piven J, Vieland V, et al. Evidence supporting WNT2 as an autism susceptibility gene. Am J Med Genet (Neuropsychiatr Genet). 2001;105:406-413.
146. Zilbovicius M, Garreau B, Samson Y, et al. Delayed maturation of the frontal cortex in childhood autism. Am J Psychiatry. 1995;152:248-252.
147. Zilbovicius M, Boddaert N, Belin P, et al. Temporal lobe dysfunction in childhood autism: a PET study. Am J Psychiatry. 2000;157:1988-1993.
148. Ohnishi T, Matsuda H, Hashimoto T, et al. Abnormal regional cerebral blood flow in childhood autism. Brain. 2000;123:1838-1844.
149. Boddaert N, Zilbovicius M. Functional neuroimaging and childhood autism. Pediatr Radiol. 2002;32:1-7.
150. Allen G, Courchesne E. Differential effects of developmental cerebellar abnormality on cognitive and motor functions in the cerebellum: an fMRI study of autism. Am J Psychiatry. 2003;160:262-273.
151. Chuganie D, Muzik O, Rothermel R, et al. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol. 1997;42:666-669.
152. McDougle C, Kresch L, Posey D. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord. 2000;30;427-435.